PTPN11 and neoplasm: Triple-negative cancer, high-grade serous carcinoma, and stomach cancer are examples of hard-to-treat wild-type RAS tumor cells that exhibit adaptive resistance that can be overcome by combining MEK inhibitors with SHP2 inhibitors (107, 194).